HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bruce E Johnson Selected Research

Erlotinib Hydrochloride (CP 358,774)

11/2021Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
12/2016A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
9/2016Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
4/2016Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
3/2016Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
8/2015Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
9/2014Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
11/2013Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
11/2013ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
8/2013Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bruce E Johnson Research Topics

Disease

90Neoplasms (Cancer)
01/2022 - 03/2002
81Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 06/2002
34Lung Neoplasms (Lung Cancer)
03/2022 - 05/2004
15Adenocarcinoma of Lung
01/2019 - 06/2004
14Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2019 - 02/2002
12Neoplasm Metastasis (Metastasis)
01/2019 - 11/2002
11Disease Progression
10/2017 - 06/2002
7Brain Neoplasms (Brain Tumor)
01/2019 - 10/2005
7Malignant Mesothelioma
01/2018 - 09/2002
5Adenocarcinoma
12/2021 - 05/2004
4Exanthema (Rash)
11/2013 - 05/2004
3Osteoporosis
09/2012 - 09/2007
2Colonic Neoplasms (Colon Cancer)
01/2022 - 07/2005
2Pancreatic Neoplasms (Pancreatic Cancer)
12/2021 - 01/2018
2Breast Neoplasms (Breast Cancer)
01/2019 - 07/2006
2Melanoma (Melanoma, Malignant)
11/2018 - 07/2016
2Leukopenia
01/2018 - 07/2010
2Mesothelioma
01/2018 - 08/2008
2Circulating Neoplastic Cells
12/2016 - 03/2016
2Carcinoid Tumor (Carcinoid)
11/2014 - 05/2004
2Nausea
11/2013 - 05/2004
2Diarrhea
11/2013 - 09/2005
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2013 - 06/2013
2Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar)
05/2007 - 10/2004
2Carcinoma (Carcinomatosis)
10/2006 - 07/2003
2Carcinogenesis
06/2006 - 10/2003
1Glioblastoma (Glioblastoma Multiforme)
01/2022
1Cholangiocarcinoma
01/2022
1Ascites
01/2020
1Hypothyroidism
01/2019

Drug/Important Bio-Agent (IBA)

44ErbB Receptors (EGF Receptor)IBA
11/2021 - 09/2002
35Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2021 - 05/2005
28Gefitinib (Iressa)FDA Link
04/2016 - 05/2004
21Tyrosine Kinase InhibitorsIBA
11/2021 - 05/2005
11Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2006
9Paclitaxel (Taxol)FDA LinkGeneric
06/2013 - 06/2002
8DNA (Deoxyribonucleic Acid)IBA
01/2021 - 02/2006
8vandetanib (ZD6474)IBA
04/2016 - 09/2007
8Phosphotransferases (Kinase)IBA
08/2015 - 06/2004
8Carboplatin (JM8)FDA LinkGeneric
06/2013 - 05/2003
7Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2010 - 10/2004
6Biological ProductsIBA
01/2019 - 11/2002
5RNA (Ribonucleic Acid)IBA
12/2021 - 11/2018
5Immune Checkpoint InhibitorsIBA
11/2021 - 11/2018
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2016 - 05/2005
5Docetaxel (Taxotere)FDA Link
04/2016 - 05/2003
4AntibodiesIBA
01/2022 - 11/2008
4Pharmaceutical PreparationsIBA
12/2021 - 05/2004
4Anaplastic Lymphoma KinaseIBA
03/2020 - 10/2013
4Cisplatin (Platino)FDA LinkGeneric
01/2018 - 06/2002
4PlatinumIBA
04/2016 - 06/2013
4Bevacizumab (Avastin)FDA Link
09/2014 - 08/2008
4Cetuximab (Erbitux)FDA Link
11/2013 - 08/2005
4Proteins (Proteins, Gene)FDA Link
03/2010 - 07/2003
3CrizotinibIBA
03/2020 - 03/2017
3human ERBB2 proteinIBA
11/2017 - 02/2015
3dabrafenibIBA
10/2017 - 01/2016
3Monoclonal AntibodiesIBA
11/2013 - 07/2006
3Imatinib Mesylate (Gleevec)FDA Link
05/2004 - 08/2003
2NucleotidesIBA
01/2021 - 09/2012
2Small Cytoplasmic RNAIBA
01/2020 - 11/2018
2GemcitabineFDA Link
01/2018 - 06/2013
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
10/2017 - 11/2013
2trametinibIBA
10/2017 - 07/2016
2Mitogen-Activated Protein KinasesIBA
07/2016 - 05/2007
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
07/2016 - 05/2007
2Discoidin Domain Receptor 2IBA
11/2013 - 06/2011
2Dasatinib (BMS 354825)FDA Link
11/2013 - 06/2011
2ParaffinIBA
12/2012 - 02/2006
2Formaldehyde (Formol)FDA Link
12/2012 - 02/2006
2EverolimusFDA Link
10/2012 - 08/2007
2Estrogens (Estrogen)FDA Link
03/2011 - 02/2010
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
05/2009 - 05/2009
2LigandsIBA
11/2008 - 11/2005
2pertuzumabIBA
10/2007 - 07/2006
2Zoledronic Acid (Zometa)FDA Link
10/2007 - 09/2007
2Ectopic HormonesIBA
07/2006 - 02/2006
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
11/2005 - 02/2002
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
06/2004 - 10/2003
1binimetinibIBA
03/2022
1encorafenibIBA
03/2022
1Immunoglobulin G (IgG)IBA
01/2022
1ChemokinesIBA
01/2021
1Phenobarbital (Luminal)FDA Link
01/2021
1Small Nuclear RNA (snRNA)IBA
01/2020
1vasectrin IIIIBA
01/2019
1vasectrin II (VS II)IBA
01/2019
1Thyroid HormonesIBA
01/2019
1Methylnitronitrosoguanidine (MNNG)IBA
01/2019
1Proto-Oncogene Proteins c-metIBA
01/2019

Therapy/Procedure

66Therapeutics
01/2022 - 03/2002
30Drug Therapy (Chemotherapy)
01/2019 - 03/2002
6Radiotherapy
11/2018 - 06/2002
3Precision Medicine
01/2020 - 01/2018
3Adjuvant Chemotherapy
09/2012 - 10/2003
2Immunotherapy
01/2022 - 11/2018
2Combination Drug Therapy (Combination Chemotherapy)
10/2013 - 08/2013
2Aftercare (After-Treatment)
09/2009 - 11/2005
2Pneumonectomy (Lung Volume Reduction)
08/2009 - 02/2009
1Off-Label Use
01/2022